Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

02 May 2003 : Original article  

Therapeutic potential of PARP inhibitors in inflammatory dermatosis

L. Virag, E. Bakondi, P. Bai, K. Erdelyi, E. Szabo, P. Gergely, C. Szabo

Med Sci Monit 2003; 9(1): 75-0 :: ID: 15218

Abstract

Several inflammatory skin diseases are characterized by oxidative stress, i.e. production of reactive oxygen and nitrogen intermediates (ROI/RNI). These reactive species are capable of causing DNA damage and consequently PARP activation. Accumulating evidence point toward an important role of oxidative stress-induced PARP activation in various dermatological conditions. Most evidence supports the role of PARP activation in contact hypersensitivity (CHS). CHS is a form of delayed type of hypersensitivity reaction mediated mainly by T lymphocytes. The first phase of CHS is sensitization during which administration of antigens triggers the proliferation of antigen-specific T lymphocytes. In senzitized individuals, application of the same, lipofilic antigen on the skin surface results in immune-mediated inflammation (effector phase). Whereas the cellular events of the senzitization phase is well characterized, little is known about the mechanisms of the effector phase. Our previous work has demonstrated that peroxynitrite, the nitric oxide-derived reactive oxidant is produced in the oxazolone-induced murine model of contact hypersensitivity. Furthermore, we have also shown that DNA breakage and PARP activation occurs in this model. Moreover, our new data demonstrate the effectiveness of the PARP inhibitor PJ-34 in CHS. The underlining mechanisms include inhibition of migration of granulocytes, inhibition of chemokine production and prevention of keratinocyte dysfunction. Sporadic data in the literature also indicate a possible role of PARP activation in other skin diseases such as sunburn erythema, toxic epidermal necrolysis or Stevens-Johnson syndrom. Proposed mechanisms for the role of poly-ADP-ribosylation in these dermatological diseases and opportunities for therapeutic interventions will be discussed.

Keywords: peroxynitrite, poly(ADP-ribose) polymerase, Dermatitis, contact hypersensitivity, Sunburn

Add Comment 0 Comments

Editorial

01 March 2024 : Editorial  

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Dinah V. Parums

DOI: 10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

In Press

18 Mar 2024 : Clinical Research  

Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative Study

Med Sci Monit In Press; DOI: 10.12659/MSM.944136  

0:00

21 Feb 2024 : Clinical Research  

Potential Value of HSP90α in Prognosis of Triple-Negative Breast Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.943049  

22 Feb 2024 : Review article  

Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943168  

23 Feb 2024 : Clinical Research  

A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943732  

Most Viewed Current Articles

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750